This article aims to review and summarize the current knowledge related to metalloproteinases in patients with spondyloarthritis.
To examine the association between matrix metalloproteinases and spondyloarthritis, we conducted a narrative review using a literature search in SCOPUS for English-language sources. The search included studies published from the database inception to December 2020.
A total number of 74 articles were included. It was found that levels of matrix metalloproteinases 3 were higher in radiographic axial spondyloarthritis patients and seemed to play a role in the progression of joint damage. The levels of matrix metalloproteinases 1, 2, and 9 were upregulated in psoriatic arthritis patients compared to psoriasis and could identify psoriasis patients who would develop rheumatic manifestations. The levels of matrix metalloproteinases correlated significantly with disease activity in ankylosing spondylitis and decreased upon treatment with Tumor Necrosis Factor inhibitors (TNFi).
Excessive matrix metalloproteinases activity is associated with articular destruction. Their levels can reflect disease activity, structural damage, and response to TNFi in patients with spondyloarthritis. Nevertheless, further studies are needed to confirm these results.
目的:本文旨在回顾和总结脊柱关节炎患者与金属蛋白酶相关的最新知识。
方法:为了检查基质金属蛋白酶与脊柱关节炎之间的关系,我们使用SCOPUS中的文献检索英语资源进行了叙述性审查。搜索包括从数据库开始到2020年12月发表的研究。
结果:共纳入74篇文章。发现放射学轴向脊柱关节炎患者的基质金属蛋白酶3水平较高,似乎在关节损伤的进展中起作用。与银屑病相比,银屑病关节炎患者的基质金属蛋白酶1、2和9的水平上调,可以识别出可能出现风湿性表现的银屑病患者。在强直性脊柱炎中,基质金属蛋白酶水平与疾病活动性显著相关,并且在用肿瘤坏死因子抑制剂(TNFi)治疗后降低。
结论:过度的基质金属蛋白酶活性与关节破坏有关。它们的水平可以反映疾病活动,结构损伤,脊柱关节炎患者对TNFi的反应。然而,需要进一步的研究来证实这些结果.